Vienna (OTS) –Antibody-mediated rejection (AMR) is among the maximum not unusual reasons of kidney transplant failure. Then again, there may be recently no remedy to be had that might struggle this complication in the longer term. As a part of a world and multidisciplinary scientific learn about led by means of Georg Böhmig and Katharina Mayer, Medical Department of Nephrology and Dialysis, College Health center for Inside Medication III of MedUni Vienna and Vienna Basic Health facility, a brand new healing theory in transplant medication has confirmed to be secure and extremely efficient. The consequences have been lately printed within the extremely revered “New England Magazine of Medication”.
The analysis concerned 22 sufferers who have been identified with antibody-mediated rejection (AMR) after a kidney transplant between 2021 and 2023 on the College Health facility AKH Vienna and the Charité – Universitätsmedizin Berlin. Within the randomized, double-blind and placebo-controlled learn about, the sufferers got both the substance felzartamab or a drug without a pharmacological impact (placebo).
Felzartamab is a particular (monoclonal CD38) antibody that used to be firstly evolved as an immunotherapy for the remedy of a couple of myeloma to struggle tumor cells within the bone marrow. “Because of its possible to persuade immune reactions in an excessively particular manner, Felzartamab additionally got here into focal point in transplant medication,” says learn about chief Georg Böhmig about fresh traits which are in large part because of his initiative. “Our function used to be to check the security and tolerability of the antibody as the primary imaginable remedy possibility for AMR after kidney transplants,” provides lead writer Katharina Mayer. After a six-month remedy segment and an similarly lengthy remark duration of the learn about contributors, the researchers have been ready to document promising effects: Above all, the morphological and molecular examinations of transplant biopsies point out that Felzartamab has the prospective to successfully and safely struggle AMR after kidney transplants.
Conceivable step forward accomplished With round 330 according to 12 months, kidney transplants are the most typical type of organ transplant in Austria. Antibody-Mediated Rejection (AMR) is among the maximum not unusual headaches. This happens when the immune device of the organ recipient develops antibodies in opposition to the transplant. The results of this is a lack of serve as of the organ, which may end up in renewed dialysis treatment and even every other transplant. Treating AMR is due to this fact very important no longer just for the well being of the sufferers, but additionally for the environment friendly use of the already scarce donor organs. “The result of our learn about may just constitute a step forward within the remedy of AMR after kidney transplants,” says Katharina Mayer. “As well as, our findings give reason why to pray that felzartamab may just additionally counteract rejection of different donor organs akin to the center or lungs. Xenotransplantations of genetically changed pig organs may just additionally most likely turn into extra imaginable consequently,” says Georg Böhmig, having a look with a bit of luck to the longer term.
Nice hope for transplant medication As the primary scientific analysis to exhibit an efficient measure for AMR, the interdisciplinary segment II learn about used to be performed in cooperation with a number of specialist departments of MedUni Vienna and AKH Vienna, such because the College Health center for Medical Pharmacology (Bernd Jilma), and at a world stage with the Charité – Universitätsmedizin Berlin (Klemens Budde), the College Health facility Basel, the College of Alberta, Canada, and the USA start-up Human Immunology Biosciences. As a prerequisite for the drug’s approval, the consequences should be showed in the next move in a multi-center segment III learn about, which is already being deliberate in response to the present learn about effects.
Publikation: New England Magazine of Medication A Randomized Section 2 Trial of Felzartamab in Antibody-Mediated Rejection Katharina A. Mayer, Eva Schrezenmeier, Matthias Diebold, Philip F. Halloran, Martina Schatzl, Sabine Schranz, Susanne Haindl, Silke Kasbohm, Alexander Kainz, Farsad Eskandary, Konstantin Doberer, Uptal D. Patel, Jaideep S. Dudani, Heinz Regele, Nicolas Kozakowski, Johannes Kläger, Rainer Boxhammer, Kerstin Amann, Elisabeth Puchhammer-Stöckl, Hannes Vietzen, Julia Beck, Ekkehard Schütz, Aylin Akifova, Christa Firbas, Houston N. Gilbert, Bilgin Osmanodja, Fabian Halleck, Bernd Jilma, Klemens Budde, Georg A. Böhmig
Inquiries & Touch:
clinical college Vienna Magazine. Johannes Angerer Head of Communications and Public Family members +431 40160-1150, +43 664 80016 11501 johannes.angerer@meduniwien.ac.at
College Health facility AKH Vienna Karin Fehringer, MBA Head of Knowledge Middle and PR Vienna Well being Community Tel.: +43 1 404 00-12160 E-Mail: presse@akhwien.at Währinger Gürtel 18-20, 1090 Vienna www.akhwien.at/presse
